Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 21:8:553960.
doi: 10.3389/fped.2020.553960. eCollection 2020.

Enteroadsorbent Polymethylsiloxane Polyhydrate vs. Probiotic Lactobacillus reuteri DSM 17938 in the Treatment of Rotaviral Gastroenteritis in Infants and Toddlers, a Randomized Controlled Trial

Leo Markovinović  1 , Ivica Knezović  1 , Tihana Kniewald  1 , Lorna Stemberger Marić  1   2 , Vladimir Trkulja  3 , Goran Tešović  1   3
Affiliations

Enteroadsorbent Polymethylsiloxane Polyhydrate vs. Probiotic Lactobacillus reuteri DSM 17938 in the Treatment of Rotaviral Gastroenteritis in Infants and Toddlers, a Randomized Controlled Trial

Leo Markovinović et al. Front Pediatr. .

Abstract

Purpose: The aim of this study was to compare two adjunct therapies in the treatment of childhood rotavirus gastroenteritis (RVGE). We compared the recommended treatment, probiotic Lactobacillus reuteri DSM 17938 (BioGaia®), vs. a novel treatment, enterosorbent polymethylsiloxane polyhydrate (Enterosgel®). Methods: This was an open-label, randomized, clinical controlled trial at the University Hospital for Infectious Diseases (UHID) in Zagreb, Croatia. A total of 149 children aged 6-36 months with acute rotaviral gastroenteritis over a period of <48 h, with no significant chronic comorbidity, were randomized to receive the standard therapy with L. reuteri DSM 17938 (hereafter L. reuteri) or polymethylsiloxane polyhydrate (hereafter PMSPH) therapy, during 5 days. The primary end point was time to recovery in days in both groups. The recovery was defined as absence of fever and vomiting and either the first firm stool, absence of stool for more than 24 h, or return of usual bowel habit. Results: A total of 75 children were randomized into the L. reuteri group and 74 were randomized into the PMSPH group; after excluding missing data, the data from 65 children in each group were analyzed. There was no significant difference in the treatment efficacy between the two regimens with an estimated median time of recovery of 6 days in both groups (p = 0.754). No significant side effects were observed in either group. Conclusion: Novel enterosorbent PMSPH had a similar efficacy to probiotic L. reuteri in the treatment of rotaviral gastroenteritis in preschool children. Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT04116307 [October 3, 2019] (retrospectively registered). https://clinicaltrials.gov/show/NCT04116307.

Keywords: Lactobacillus reuteri DSM 17938; children; gastroenteritis; polymethylsiloxane polyhidrate; rotavirus.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
CONSORT flow diagram of the randomized trial of children with rotavirus infection.
Figure 2
Figure 2
Kaplan–Meier curves of cumulative recovery in the PMSPH (Enterosgel®) and L. reuteri (BioGaia®) treatment groups for children with RVGE.
Figure 3
Figure 3
Kaplan–Meier curves of cumulative hospital discharge for the PMSPH (Enterosgel®) and L. reuteri (BioGaia®) treatment groups for children with RVGE.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. World Health Organization Diarrhoeal Disease. (2017). Available online at: http://www.who.int/mediacentre/factsheets/fs330/en/ (accessed April 12, 2018).
    1. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis. (2003) 9:565–72. 10.3201/eid0905.020562 - DOI - PMC - PubMed
    1. Croatian Institute of Public Health Implementation of Immunization, Immunoprophylaxis and Chemoprophylaxis Program in Croatia in 2017 (2017). Available online at: https://www.hzjz.hr/wp-content/uploads/2017/05/PROVEDBENI-PROGRAM-II._20... (accessed November 20, 2020).
    1. Dormitzer PR. Rotavirus. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett's: Principles and Practice of Infectious Diseases. 9th ed Philadelphia, PA: Churchill Livingstone; (2020). p. 1983–96.
    1. Isolauri E, Juntunen M, Rautanen T, Sillanaukee P, Koivula T. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics. (1991) 88:90–7. - PubMed

Associated data